An observational study in Transcatheter Mitral Valve Edge-to-Edge Repair System and Biodegradable Patent Foramen Ovale Closure Device, sponsored by Shanghai Jiao Tong University School of Medicine. Recruiting at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Shanghai Jiao Tong University School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Foramen Ovale, Patent with a site in China — 13 open to participants now, 13 under way, none of them phase 3. Foramen Ovale, Patent · China.
Among the 20 studies in Foramen Ovale, Patent with a site in China, this one is one of 2 that started in 2025, is one of 6 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 20th registered.
137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.
Browse Foramen Ovale, Patent studies →13 of the 20 studies in Foramen Ovale, Patent with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 18–60
Sichuan University · Sites in China
Ages 18–60
Chinese Academy of Medical Sciences, Fuwai Hospital · Sites in China
Ages 18–65
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–65
Peking University Third Hospital · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 34 Foramen Ovale, Patent studies recruiting now, 11 (32%) set no upper age limit and 19 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,200 is above the median of 252 across 60 observational studies indexed under Foramen Ovale, Patent.
Median enrollment 211 across the 14 interventional studies, 565 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
Shanghai Jiao Tong University School of Medicine is the lead sponsor of 374 studies on the registry; 110 are open to participants now.
Shanghai Jiao Tong University School of Medicine has 1 study filed under Foramen Ovale, Patent — fewer than ten, so there is no comparison to draw.
4 of the studies in Foramen Ovale, Patent with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06347276China National Center for Cardiovascular DiseasesCerebral Microembolization Associated With PFO Closure | 2026-12-31 |
| NCT06953622Peking University Third HospitalEstablishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale | 2026-12-31 |
| NCT07170176First Affiliated Hospital Xi'an Jiaotong UniversityEffects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine | 2027-05-31 |
| NCT06863350Sichuan UniversityPercutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale(PREDICT-PFO Trial) | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies in Foramen Ovale, Patent with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to establish an active surveillance system to evaluate the safety and effectiveness of innovative medical devices used in the interventional treatment of structural heart disease. The devices of interest include a biodegradable patent foramen ovale (PFO) closure device and a transcatheter mitral valve edge-to-edge repair system. Clinical information from patients receiving these devices during routine clinical care will be collected and analyzed. The findings will help evaluate the safety and effectiveness of these devices and support the development of appropriate clinical evaluation indicators and long-term monitoring strategies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The participant expresses a desire to withdraw from the study.
Participants with patent foramen ovale (PFO) who receive a biodegradable PFO closure device as part of routine clinical care will be included in this cohort. Clinical data will be collected to evaluate the safety and effectiveness of the device during follow-up.
Participants with degenerative or functional mitral regurgitation who undergo transcatheter mitral valve edge-to-edge repair using a transcatheter mitral valve edge-to-edge repair system. Safety and effectiveness outcomes will be assessed during follow-up.
Incidence of Major Adverse Events
Incidence of major adverse events related to the biodegradable PFO closure or transcatheter mitral valve edge-to-edge repair procedure during follow-up.
Time frame: At 1, 6, and 12 months after the procedure
Anatomical success of PFO closure within 12 months after biodegradable PFO occluder implantation, assessed by transthoracic echocardiography
The proportion of participants achieving successful anatomical closure of the patent foramen ovale (PFO) during the 12-month follow-up period after biodegradable PFO occluder implantation, assessed by transthoracic echocardiography.
Time frame: At 1, 6, and 12 months after the procedure
Incidence of the composite clinical outcome of heart failure hospitalization, all-cause mortality, or cardiovascular mortality within 12 months after transcatheter edge-to-edge mitral valve repair
The proportion of participants experiencing at least one of the following events during the 12-month follow-up period after TEER: hospitalization for heart failure, all-cause death, or cardiovascular death. Events will be assessed through clinical follow-up and review of medical records.
Time frame: At 1, 6, and 12 months after the procedure
Degree of device degradation
The degree of degradation of the biodegradable PFO closure device will be assessed by echocardiography during follow-up.
Time frame: At 1, 6, and 12 months after the procedure
Incidence of residual shunt after PFO closure
The presence of residual shunt after implantation of the biodegradable PFO closure device will be assessed by echocardiography with contrast study, when applicable.
Time frame: At 1, 6, and 12 months after the procedure.
Incidence of re-intervention after PFO closure
The percentage of participants requiring reapeat intervention or surgical treatment related to the PFO closure device during follow-up.
Time frame: At 1, 6, and 12 months after the procedure.
Incidence of recurrent stroke after PFO closure
The occurrence of recurrent ischemic or hemorrhagic stroke during the follow-up period will be assessed by clinical evaluation and review of medical records.
Time frame: At 1, 6, and 12 months after the procedure.
Incidence of device-related thrombosis after PFO closure
The occurrence of thrombosis related to the biodegradable PFO closure device during follow-up will be assessed by echocardiography and clinical assessment.
Time frame: At 1, 6, and 12 months after the procedure.
Proportion of participants who underwent TEER and achieved immediate procedural success
Immediate procedural success is defined as successful completion of the transcatheter mitral valve edge-to-edge repair procedure with post-procedural mitral regurgitation (MR) grade ≤2+, as assessed by echocardiography.
Time frame: Within 24 hours after the procedure.
Incidence of subsequent open-heart surgery in the TEER group
The number of participants undergoing subsequent open-heart surgery related to TEER during follow-up.
Time frame: At 1, 6, and 12 months after the procedure.
Incidence of ischemic or hemorrhagic stroke in the TEER group
The occurrence of ischemic or hemorrhagic stroke during follow-up in the TEER group will be assessed by clinical evaluation and review of medical records.
Time frame: At 1, 6, and 12 months after the procedure.
Incidence of bleeding events in the TEER group
The occurrence of bleeding events during follow-up in the TEER group will be assessed by clinical evaluation and review of medical records.
Time frame: At 1, 6, and 12 months after the procedure.
Plan to share: Yes — De-identified individual participant-level data relevant to the study objectives, including baseline characteristics, procedural data, safety and efficacy outcomes, and follow-up data, will be shared.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Start Date: 12 months after publication of the primary results End Date: No end date
Access criteria: De-identified individual participant-level data and supporting information will be available to qualified researchers upon reasonable request and subject to review and approval by the study investigators. Access will be provided for scientifically justified research purposes in accordance with applicable regulations and data protection requirements. Requests should be submitted to the study investigators, and approved data will be shared through a secure data transfer mechanism.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Jan 2029, 37 months after the start.
Of 29 observational studies under Foramen Ovale, Patent, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 92. This study's planned 37 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Jiao Tong University School of Medicine →